Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study
Carregando...
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
CORREIA, Marcia Regina Silva
Citação
DIABETOLOGY & METABOLIC SYNDROME, v.6, article ID 103, 7p, 2014
Resumo
Background: Blood glucose control is fundamental albeit not enough to prevent diabetic macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors are effective in improving metabolic parameters in patients with type 2 diabetes mellitus (T2DM) but little is known about its cardiovascular effects. We compared the DPP-4 inhibitor sitagliptin with bedtime NPH insulin (NPH) as add-on therapy in patients with T2DM, aiming to ascertain which drug would have additional cardioprotective effects. Methods: Thirty-five T2DM patients inadequately controlled with metformin plus glyburide were randomized to receive sitagliptin (n = 18) or NPH (n = 17) for 24 weeks. Fasting plasma glucose, HbA1c, lipid profile, C-reactive protein, active glucagon-like peptide (aGLP-1) levels, 24-hour ambulatory blood pressure measurement and comprehensive 2-dimensional echocardiogram were determined before and after treatments. Results: Both sitagliptin and NPH therapies decreased HbA1c levels after 24 weeks. Fasting plasma glucose and triglyceride levels decreased in the NPH group whereas only sitagliptin increased aGLP-1 levels. Left ventricular diastolic dysfunction (LVDD) was detected in 58.6% of twenty-nine patients evaluated. Beneficial effects in LVDD were observed in 75% and 11% of patients treated with sitagliptin and NPH, respectively (p = 0.015). Neither therapy changed C-reactive protein or blood pressure. Conclusions: Sitagliptin and bedtime NPH were similarly effective on glucose control. Improvement in LVDD in T2DM patients treated with sitagliptin was suggested, probably related to the increase of aGLP-1 levels. Therefore, DPP-4 inhibitor seems to have cardioprotective effects independent of glucose control and may have a role in the prevention of diabetic cardiomyopathy.
Palavras-chave
Type 2 diabetes mellitus (T2DM), Dypeptidil-peptidase-4 inhibitor, Bedtime NPH insulin, Cardiovascular function, Glucagon-like peptide 1
Referências
- American Diabetes Association, 2004, DIABETES CARE S1, V27, pS5, DOI 10.2337/DIACARE.27.2007.S5
- Boyer JK, 2004, AM J CARDIOL, V93, P870, DOI 10.1016/j.amjcard.2003.12.026
- Chang GL, 2013, EUR J PHARMACOL, V718, P105, DOI [10.1016/j.ejphar.2013.09.007, 10.1010/j.ejphar.2013.09.007]
- COHN JN, 1990, CIRCULATION, V81, P48
- Cosson S, 2003, DIABETES METAB, V29, P455, DOI 10.1016/S1262-3636(07)70059-9
- Currie CJ, 2013, J CLIN ENDOCR METAB, V98, P668, DOI 10.1210/jc.2012-3042
- Dinh W, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-63
- dos Santos L, 2013, CIRC-HEART FAIL, V6, P1029, DOI 10.1161/CIRCHEARTFAILURE.112.000057
- HIRAMATSU K, 1992, AM J CARDIOL, V70, P1185, DOI 10.1016/0002-9149(92)90053-2
- Marney A, 2010, HYPERTENSION, V56, P728, DOI 10.1161/HYPERTENSIONAHA.110.156554
- Martin JH, 2011, INTERN MED J, V41, P299, DOI 10.1111/j.1445-5994.2011.02439.x
- Monami M, 2013, DIABETES OBES METAB, V15, P112, DOI 10.1111/dom.12000
- Mor-Avi V, 2011, J AM SOC ECHOCARDIOG, V24, P277, DOI 10.1016/j.echo.2011.01.015
- Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023
- Nikolaidis AL, 2004, CIRCULATION, V109, P962
- Patil HR, 2010, AM J CARDIOL, V110, P826
- Picatoste B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078330
- Post S, 2012, J MOL CELL CARDIOL, V53, P899, DOI 10.1016/j.yjmcc.2012.08.026
- RAEV DC, 1994, DIABETES CARE, V17, P633, DOI 10.2337/diacare.17.7.633
- Read PA, 2010, CIRC-CARDIOVASC IMAG, V3, P195, DOI 10.1161/CIRCIMAGING.109.899377
- Saxena A, 2008, CIRCULATION, V117, P224
- Scheen AJ, 2011, POSTGRAD MED, V125, P7
- Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684
- Shimabukuro M, 2011, DIABETES CARE, V34, P686, DOI 10.2337/dc10-1141
- Sokos GG, 2007, AM J CARDIOL, V100, P824, DOI 10.1016/j.amjcard.2007.05.022
- Sonne DP, 2008, REGUL PEPTIDES, V146, P243, DOI 10.1016/j.regpep.2007.10.001
- Theiss HD, 2013, INT J CARDIOL, V168, P3359, DOI 10.1016/j.ijcard.2013.04.121
- Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005
- Ye YM, 2010, AM J PHYSIOL-HEART C, V298, pH1454, DOI 10.1152/ajpheart.00867.2009